clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT00942578 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P17 | country | United States of America | Q30 |
P582 | end time | 2017-07-31 | |
P921 | main subject | metastatic prostate carcinoma | Q55779807 |
P4135 | maximum age | 100 | |
P2899 | minimum age | 18 | |
P1132 | number of participants | 63 | |
P4844 | research intervention | bevacizumab | Q413299 |
prednisone | Q424972 | ||
(RS)-lenalidomide | Q425681 | ||
P6153 | research site | National Institutes of Health | Q390551 |
P580 | start time | 2009-07-16 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer |
Search more.